A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506881-30-00

Acronym

CGME751A12101

Enrollment

136

Registered

2024-04-09

Start date

2024-05-15

Completion date

Unknown

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Italy, Lithuania, Romania, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026